Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 2/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | RECQL | P46063 | 1/20 | 0.32 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.32 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.32 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.32 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16411011 | 0.84 | ALDH1A1 (0.31) | ALDH1A1MAPTHPGDRECQL | |
| SCHEMBL10500046 | 0.82 | ALDH1A1 (0.36) | ALDH1A1MAPTHPGDRECQLKEAP1 | |
| SCHEMBL6378778 | 0.81 | — | — | |
| SCHEMBL3358239 | 0.81 | — | — | |
| SCHEMBL2474496 | 0.81 | ALDH1A1 (0.43) | ALDH1A1MAPTHPGDRECQLKEAP1 | |
| SCHEMBL18594806 | 0.81 | ALDH1A1 (0.33) | ALDH1A1RECQL | |
| Hydrochloric Acid SCHEMBL27994744 | 0.79 | — | — | |
| SCHEMBL10971698 | 0.76 | ALDH1A1 (0.39) | ALDH1A1MAPTHPGDRECQLKEAP1 | |
| SCHEMBL11551158 | 0.74 | ALDH1A1 (0.43) | ALDH1A1MAPTHPGDRECQLKEAP1 | |
| SCHEMBL9397762 | 0.74 | ALDH1A1 (0.43) | ALDH1A1MAPTHPGDRECQLKEAP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230047816-A1 | PFKFB3 INHIBITORS AND THEIR USES | GERO PTE. LTD. (SG) | 2023-02-16 | — | — | US | disclosed |
| US-9757369-B2 | Heterocyclic GSK-3 allosteric modulators | CONSEJO SUPERIOR DE INVESTIGACIONES CIENTIFICAS (CSIC) (ES) | 2017-09-12 | — | — | US | disclosed |
| US-20170196850-A1 | Heterocyclic GSK-3 Allosteric Modulators | CONSEJO SUPERIOR DE INVESTIGACIONES CIENTIFICAS (CSIC) (ES) | 2017-07-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230047816-A1 | PFKFB3 INHIBITORS AND THEIR USES | PFKFB3, PFKFB4, PFKFB1 | ALDH1A1 1943/4885MAPT 845/4885HPGD 980/4885 |
| US-20170196850-A1 | Heterocyclic GSK-3 Allosteric Modulators | GSK3B, GSK3A, GSKIP | ALDH1A1 3820/4885MAPT 326/4885HPGD 2265/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.